Hyperfine Inc (HYPR)vsStryker Corporation (SYK)
HYPR
Hyperfine Inc
$1.17
+1.74%
HEALTHCARE · Cap: $120.49M
SYK
Stryker Corporation
$327.65
-0.26%
HEALTHCARE · Cap: $125.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 185080% more annual revenue ($25.12B vs $13.56M). SYK leads profitability with a 12.9% profit margin vs -2.6%. SYK earns a higher WallStSmart Score of 65/100 (C+).
HYPR
Avoid25
out of 100
Grade: F
SYK
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HYPR.
Margin of Safety
+16.8%
Fair Value
$393.59
Current Price
$327.65
$65.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 128.0% year-over-year
Reasonable price relative to book value
Earnings expanding 55.9% YoY
Large-cap with strong market position
Strong operational efficiency at 27.2%
Generating 1.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -79.0% — below average capital efficiency
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : HYPR
The strongest argument for HYPR centers on Revenue Growth, Price/Book. Revenue growth of 128.0% demonstrates continued momentum.
Bull Case : SYK
The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.
Bear Case : HYPR
The primary concerns for HYPR are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
HYPR profiles as a hypergrowth stock while SYK is a value play — different risk/reward profiles.
HYPR carries more volatility with a beta of 1.11 — expect wider price swings.
HYPR is growing revenue faster at 128.0% — sustainability is the question.
SYK generates stronger free cash flow (1.9B), providing more financial flexibility.
Bottom Line
SYK scores higher overall (65/100 vs 25/100) and 11.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hyperfine Inc
HEALTHCARE · MEDICAL DEVICES · USA
Hyperfine Inc. is a pioneer in medical technology, focusing on transforming access to MRI with innovative point-of-care imaging solutions. As the developer of the first FDA-cleared portable MRI system, the company significantly enhances patient care by delivering high-quality imaging directly at the bedside, which streamlines clinical decision-making. By emphasizing cost efficiency and patient convenience, Hyperfine is strategically positioned to capitalize on the escalating demand for advanced diagnostic imaging solutions in a rapidly changing healthcare environment. Its groundbreaking technology is poised to make a substantial impact on healthcare delivery across various medical settings, representing a promising opportunity for institutional investors.
Visit Website →Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?